Novo Nordisk A/S (NVO) has declined -0.65% and closed its last trading session at $49.06.
Now we will discuss the financial strength of Novo Nordisk A/S. The company’s average Piotroski F-Score: 6 during the last 7 years. Its mean Altman Z-Score: 13.37 during the last 7 years, while average Beneish M-Score: -2.91 during the last 7 years.
Revenue growth shows increase or decrease in sales over time. It is used to find out how fast a business is expanding. The average revenue per share growth rate of Novo Nordisk A/S during the past 12 months was 5.4 percent.
EBITDA margin is an indicator of a company’s operating profitability as a percentage of its overall revenue. It is equal to earnings before interest, tax, depreciation and amortization (EBITDA) divided by overall revenue. Novo Nordisk A/S’s average EBITDA per Share Growth Rate was 21.8 percent during the past 12 months.
The Relative Strength Index (RSI), developed by J. Welles Wilder, is a momentum oscillator that calculates the speed and change of price movements. The RSI oscillates between zero and 100. Relative Strength Index (RSI-14) for Novo Nordisk A/S (NVO) is at 57.25.
Analysts look for public financial statements, listen in on conference calls and talk to managers and customers of a company in order to reach an opinion and communicate the value of a stock. Ultimately, through all this investigation into the company’s performance the analyst decides if their stock is a “buy,” sell” or hold.”
Novo Nordisk A/S was covered by a number of analysts recently, 0 rated the stock as Buy, 0 rated Outperform, 1 rated Hold, 0 gave an Underperform and 0 rated sell.
Earnings per share (EPS) is the portion of a company’s profit allocated to each outstanding share of common stock. Earnings per share serves as an indicator of a company’s profitability. Consensus earnings estimates are far from perfect, but they are watched by many investors and play an important role in measuring the appropriate valuation for a stock. Investors measure stock performance on the basis of a company’s earnings power. To make a proper assessment, investors seek a sound estimate of this year’s and next year’s earnings per share (EPS), as well as a strong sense of how much the company will earn even farther down the road.
The company’s Average Earnings Estimate for the Current Fiscal quarter is $0.53, according to consensus of 1 analyst. They are also projecting the Low EPS estimate of $0.53 and the High EPS estimate of $0.53.
Revenue is the amount of money that a company actually receives during a specific period, including discounts and deductions for returned merchandise. It is the “top line” or “gross income” figure from which costs are subtracted to determine net income.
Novo Nordisk A/S (NVO) is expected to post revenue of $4.32 Billion in the current quarter, according to consensus of 1 analysts. The high and low revenue estimates for the current quarter are $4.32 Billion and $4.32 Billion, respectively. The company reported revenue of $0 in the same period last year.
The market capitalization of Novo Nordisk A/S is at $96.89 Billion. The company has an Average True Range (ATR) value of 0.63, while a Beta Value of 0.62. The YTD performance of the stock stands at 36.81 Percent. The Weekly and Monthly Volatility of the stock are 0.90% percent and 0.76% percent, respectively.
The SMA20 for the stock is at 0.56 percent, SMA50 stands at 4.46 percent, while SMA200 is 21.38 Percent.